25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

RAPT (Rapt) Stock Analysis
Buy, Hold or Sell?

Let's analyze Rapt together

I guess you are interested in RAPT Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Rapt’s Financial Insights
  • 📈 Technical Analysis (TA) – Rapt’s Price Targets

I'm going to help you getting a better view of RAPT Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about RAPT Therapeutics Inc

I send you an email if I find something interesting about RAPT Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Rapt (30 sec.)










1.2. What can you expect buying and holding a share of Rapt? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.29
Expected worth in 1 year
$3.20
How sure are you?
30.8%

+ What do you gain per year?

Total Gains per Share
$-0.09
Return On Investment
-1.2%

For what price can you sell your share?

Current Price per Share
$8.05
Expected price per share
$5.664 - $12.56
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Rapt (5 min.)




Live pricePrice per Share (EOD)
$8.05
Intrinsic Value Per Share
$-38.90 - $-45.80
Total Value Per Share
$-35.61 - $-42.51

2.2. Growth of Rapt (5 min.)




Is Rapt growing?

Current yearPrevious yearGrowGrow %
How rich?$177.3m$162.5m-$19.5m-13.7%

How much money is Rapt making?

Current yearPrevious yearGrowGrow %
Making money-$29.1m-$29.5m$384.7k1.3%
Net Profit Margin0.0%-146.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Rapt (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#259 / 876

Most Revenue
#707 / 876

Most Profit
#694 / 876

Most Efficient
#343 / 876
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Rapt?

Welcome investor! Rapt's management wants to use your money to grow the business. In return you get a share of Rapt.

First you should know what it really means to hold a share of Rapt. And how you can make/lose money.

Speculation

The Price per Share of Rapt is $8.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rapt.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rapt, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.29. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rapt.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.32-4.0%-0.66-8.2%-0.77-9.5%-0.70-8.7%-0.66-8.2%-0.70-8.7%
Usd Book Value Change Per Share-0.77-9.6%-0.02-0.3%-0.59-7.4%-0.20-2.5%-0.12-1.5%0.131.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.77-9.6%-0.02-0.3%-0.59-7.4%-0.20-2.5%-0.12-1.5%0.131.6%
Usd Price Per Share1.22-1.97-17.29-13.12-19.11-16.58-
Price to Earnings Ratio-0.96--0.86--5.68--4.73--7.52--6.48-
Price-to-Total Gains Ratio-1.58--2.89--28.68--11.02--23.44--20.43-
Price to Book Ratio0.37-0.67-4.10-2.69-3.69-3.22-
Price-to-Total Gains Ratio-1.58--2.89--28.68--11.02--23.44--20.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.05
Number of shares124
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.02-0.12
Usd Total Gains Per Share-0.02-0.12
Gains per Quarter (124 shares)-2.90-14.74
Gains per Year (124 shares)-11.61-58.94
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-12-220-59-69
20-23-340-118-128
30-35-460-177-187
40-46-580-236-246
50-58-700-295-305
60-70-820-354-364
70-81-940-413-423
80-93-1060-472-482
90-104-1180-530-541
100-116-1300-589-600

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.026.00.00.0%0.026.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%8.018.00.030.8%8.018.00.030.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.026.00.0%0.00.026.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%8.018.00.030.8%8.018.00.030.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of RAPT Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.774-0.023-97%-0.593-23%-0.198-74%-0.119-85%0.127-711%
Book Value Per Share--3.2943.157+4%4.233-22%4.525-27%4.955-34%3.918-16%
Current Ratio--21.11011.005+92%9.110+132%11.610+82%12.499+69%12.375+71%
Debt To Asset Ratio--0.0540.131-59%0.136-60%0.120-55%0.113-52%0.324-83%
Debt To Equity Ratio--0.0570.156-63%0.158-64%0.139-59%0.130-56%0.120-52%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--234778127.165216935505.356+8%811472955.298-71%641334527.923-63%741367535.913-68%725632845.421-68%
Eps---0.319-0.661+107%-0.768+141%-0.698+119%-0.661+107%-0.703+120%
Ev To Ebitda Ratio---3.087-2.052-34%-6.447+109%-6.045+96%-9.252+200%-9.429+205%
Free Cash Flow Per Share---0.974-0.594-39%-0.690-29%-0.608-38%-0.570-42%-0.555-43%
Free Cash Flow To Equity Per Share---0.9740.177-650%-0.623-36%-0.005-100%0.080-1314%0.222-540%
Gross Profit Margin--1.0001.0030%1.005-1%1.0030%1.0020%1.0010%
Intrinsic Value_10Y_max---45.804----------
Intrinsic Value_10Y_min---38.902----------
Intrinsic Value_1Y_max---2.749----------
Intrinsic Value_1Y_min---2.699----------
Intrinsic Value_3Y_max---9.663----------
Intrinsic Value_3Y_min---9.197----------
Intrinsic Value_5Y_max---18.268----------
Intrinsic Value_5Y_min---16.835----------
Market Cap133115605.000+51%65700127.16584051505.356-22%663738205.298-90%481584194.590-86%588703185.913-89%489442099.972-87%
Net Profit Margin----0%-1.4600%-5.1080%-9.8440%-8.1130%
Operating Margin----0%-1.5700%-5.5860%-10.2250%-8.4020%
Operating Ratio----0%1.570-100%5.722-100%10.747-100%8.842-100%
Pb Ratio2.444+85%0.3700.666-44%4.104-91%2.687-86%3.690-90%3.223-89%
Pe Ratio-6.314-560%-0.957-0.859-10%-5.683+494%-4.734+395%-7.518+686%-6.478+577%
Price Per Share8.050+85%1.2201.965-38%17.288-93%13.123-91%19.110-94%16.580-93%
Price To Free Cash Flow Ratio-2.066-560%-0.313-1.060+239%-6.298+1911%-5.583+1683%-9.375+2894%-8.518+2620%
Price To Total Gains Ratio-10.402-560%-1.576-2.885+83%-28.678+1719%-11.015+599%-23.444+1387%-20.434+1196%
Quick Ratio--34.37417.168+100%15.348+124%19.588+75%21.274+62%19.174+79%
Return On Assets---0.092-0.175+91%-0.161+76%-0.144+57%-0.127+39%-0.130+42%
Return On Equity---0.097-0.206+113%-0.188+94%-0.166+71%-0.146+50%-0.135+40%
Total Gains Per Share---0.774-0.023-97%-0.593-23%-0.198-74%-0.119-85%0.127-711%
Usd Book Value--177372000.000143000500.000+24%162586750.000+9%173285333.333+2%164078450.000+8%130002884.615+36%
Usd Book Value Change Per Share---0.774-0.023-97%-0.593-23%-0.198-74%-0.119-85%0.127-711%
Usd Book Value Per Share--3.2943.157+4%4.233-22%4.525-27%4.955-34%3.918-16%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--234778127.165216935505.356+8%811472955.298-71%641334527.923-63%741367535.913-68%725632845.421-68%
Usd Eps---0.319-0.661+107%-0.768+141%-0.698+119%-0.661+107%-0.703+120%
Usd Free Cash Flow---52457000.000-27171750.000-48%-26500250.000-49%-24161500.000-54%-19974600.000-62%-17521615.385-67%
Usd Free Cash Flow Per Share---0.974-0.594-39%-0.690-29%-0.608-38%-0.570-42%-0.555-43%
Usd Free Cash Flow To Equity Per Share---0.9740.177-650%-0.623-36%-0.005-100%0.080-1314%0.222-540%
Usd Market Cap133115605.000+51%65700127.16584051505.356-22%663738205.298-90%481584194.590-86%588703185.913-89%489442099.972-87%
Usd Price Per Share8.050+85%1.2201.965-38%17.288-93%13.123-91%19.110-94%16.580-93%
Usd Profit---17165000.000-29127250.000+70%-29512000.000+72%-26938250.000+57%-22618750.000+32%-19920961.538+16%
Usd Revenue----0%1322000.000-100%567916.667-100%768800.000-100%627346.154-100%
Usd Total Gains Per Share---0.774-0.023-97%-0.593-23%-0.198-74%-0.119-85%0.127-711%
 EOD+5 -3MRQTTM+18 -15YOY+15 -203Y+15 -205Y+15 -2010Y+15 -20

3.3 Fundamental Score

Let's check the fundamental score of RAPT Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.314
Price to Book Ratio (EOD)Between0-12.444
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than134.374
Current Ratio (MRQ)Greater than121.110
Debt to Asset Ratio (MRQ)Less than10.054
Debt to Equity Ratio (MRQ)Less than10.057
Return on Equity (MRQ)Greater than0.15-0.097
Return on Assets (MRQ)Greater than0.05-0.092
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of RAPT Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.529
Ma 20Greater thanMa 508.409
Ma 50Greater thanMa 1007.680
Ma 100Greater thanMa 2008.329
OpenGreater thanClose8.060
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About RAPT Therapeutics Inc

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-06-20 13:59:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Rapt earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of RAPT Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-146.0%+146.0%
TTM-5Y-984.4%+984.4%
5Y-984.4%10Y-811.3%-173.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM--139.0%+139.0%
YOY-146.0%-194.4%+48.4%
3Y-510.8%-248.5%-262.3%
5Y-984.4%-343.3%-641.1%
10Y-811.3%-488.9%-322.4%
4.3.1.2. Return on Assets

Shows how efficient Rapt is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • -9.2% Return on Assets means that Rapt generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of RAPT Therapeutics Inc:

  • The MRQ is -9.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.2%TTM-17.5%+8.4%
TTM-17.5%YOY-16.1%-1.4%
TTM-17.5%5Y-12.7%-4.8%
5Y-12.7%10Y-13.0%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.2%-11.6%+2.4%
TTM-17.5%-11.7%-5.8%
YOY-16.1%-11.4%-4.7%
3Y-14.4%-11.9%-2.5%
5Y-12.7%-12.0%-0.7%
10Y-13.0%-13.8%+0.8%
4.3.1.3. Return on Equity

Shows how efficient Rapt is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • -9.7% Return on Equity means Rapt generated $-0.10 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of RAPT Therapeutics Inc:

  • The MRQ is -9.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.7%TTM-20.6%+10.9%
TTM-20.6%YOY-18.8%-1.8%
TTM-20.6%5Y-14.6%-6.0%
5Y-14.6%10Y-13.5%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.7%-13.5%+3.8%
TTM-20.6%-15.0%-5.6%
YOY-18.8%-14.5%-4.3%
3Y-16.6%-16.9%+0.3%
5Y-14.6%-17.7%+3.1%
10Y-13.5%-19.9%+6.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of RAPT Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Rapt is operating .

  • Measures how much profit Rapt makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of RAPT Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-157.0%+157.0%
TTM-5Y-1,022.5%+1,022.5%
5Y-1,022.5%10Y-840.2%-182.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.5%+232.5%
TTM--250.3%+250.3%
YOY-157.0%-208.4%+51.4%
3Y-558.6%-221.7%-336.9%
5Y-1,022.5%-344.1%-678.4%
10Y-840.2%-470.4%-369.8%
4.3.2.2. Operating Ratio

Measures how efficient Rapt is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1.570-1.570
TTM-5Y10.747-10.747
5Y10.74710Y8.842+1.905
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.108-2.108
TTM-2.680-2.680
YOY1.5703.080-1.510
3Y5.7223.621+2.101
5Y10.7474.734+6.013
10Y8.8426.546+2.296
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of RAPT Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Rapt is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 21.11 means the company has $21.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 21.110. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.005. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ21.110TTM11.005+10.106
TTM11.005YOY9.110+1.895
TTM11.0055Y12.499-1.494
5Y12.49910Y12.375+0.124
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.1103.616+17.494
TTM11.0053.826+7.179
YOY9.1104.141+4.969
3Y11.6104.661+6.949
5Y12.4995.756+6.743
10Y12.3756.149+6.226
4.4.3.2. Quick Ratio

Measures if Rapt is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • A Quick Ratio of 34.37 means the company can pay off $34.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 34.374. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.168. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ34.374TTM17.168+17.206
TTM17.168YOY15.348+1.820
TTM17.1685Y21.274-4.106
5Y21.27410Y19.174+2.101
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.3742.799+31.575
TTM17.1683.143+14.025
YOY15.3483.794+11.554
3Y19.5884.307+15.281
5Y21.2745.707+15.567
10Y19.1746.457+12.717
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of RAPT Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Rapt assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rapt to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.05 means that Rapt assets are financed with 5.4% credit (debt) and the remaining percentage (100% - 5.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 0.054. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.131. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.054TTM0.131-0.077
TTM0.131YOY0.136-0.004
TTM0.1315Y0.113+0.018
5Y0.11310Y0.324-0.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0540.327-0.273
TTM0.1310.348-0.217
YOY0.1360.327-0.191
3Y0.1200.340-0.220
5Y0.1130.349-0.236
10Y0.3240.379-0.055
4.5.4.2. Debt to Equity Ratio

Measures if Rapt is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rapt to the Biotechnology industry mean.
  • A Debt to Equity ratio of 5.7% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of RAPT Therapeutics Inc:

  • The MRQ is 0.057. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.156. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.057TTM0.156-0.098
TTM0.156YOY0.158-0.002
TTM0.1565Y0.130+0.026
5Y0.13010Y0.120+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0570.379-0.322
TTM0.1560.435-0.279
YOY0.1580.412-0.254
3Y0.1390.448-0.309
5Y0.1300.460-0.330
10Y0.1200.509-0.389
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Rapt generates.

  • Above 15 is considered overpriced but always compare Rapt to the Biotechnology industry mean.
  • A PE ratio of -0.96 means the investor is paying $-0.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of RAPT Therapeutics Inc:

  • The EOD is -6.314. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.957. Based on the earnings, the company is expensive. -2
  • The TTM is -0.859. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.314MRQ-0.957-5.357
MRQ-0.957TTM-0.859-0.098
TTM-0.859YOY-5.683+4.824
TTM-0.8595Y-7.518+6.660
5Y-7.51810Y-6.478-1.041
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.314-2.303-4.011
MRQ-0.957-2.062+1.105
TTM-0.859-2.541+1.682
YOY-5.683-3.741-1.942
3Y-4.734-3.754-0.980
5Y-7.518-6.136-1.382
10Y-6.478-6.686+0.208
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of RAPT Therapeutics Inc:

  • The EOD is -2.066. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.313. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.060. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.066MRQ-0.313-1.753
MRQ-0.313TTM-1.060+0.747
TTM-1.060YOY-6.298+5.238
TTM-1.0605Y-9.375+8.315
5Y-9.37510Y-8.518-0.857
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.066-3.178+1.112
MRQ-0.313-2.700+2.387
TTM-1.060-3.619+2.559
YOY-6.298-4.357-1.941
3Y-5.583-5.065-0.518
5Y-9.375-8.478-0.897
10Y-8.518-9.275+0.757
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Rapt is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.37 means the investor is paying $0.37 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of RAPT Therapeutics Inc:

  • The EOD is 2.444. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.370. Based on the equity, the company is cheap. +2
  • The TTM is 0.666. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.444MRQ0.370+2.074
MRQ0.370TTM0.666-0.295
TTM0.666YOY4.104-3.439
TTM0.6665Y3.690-3.025
5Y3.69010Y3.223+0.467
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4441.963+0.481
MRQ0.3701.848-1.478
TTM0.6662.119-1.453
YOY4.1042.469+1.635
3Y2.6872.526+0.161
5Y3.6903.664+0.026
10Y3.2234.351-1.128
4.6.2. Total Gains per Share

2.4. Latest News of RAPT Therapeutics Inc

Does RAPT Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from RAPT Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-14
15:05
Rapt Therapeutics announces effective date for 1-for-8 reverse stock splitRead
2025-06-13
15:00
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock SplitRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of RAPT Therapeutics Inc.

4.8.1. Institutions holding RAPT Therapeutics Inc

Institutions are holding 99.426% of the shares of RAPT Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Medicxi Ventures Management (Jersey) Ltd2.1126.230222352000223520000
2025-03-31Orbimed Advisors, LLC1.24120.3821313526000
2025-03-31TCG Crossover Management, LLC1.23692.178513090200-45060-0.343
2025-03-31Foresite Capital Management VI LLC1.18118.35411250000000
2025-03-31RTW INVESTMENTS, LLC1.11160.21951176400000
2025-03-31Bvf Inc0.87290.4593923755600
2025-03-31Vanguard Group Inc0.78230.000282787985337449181.4626
2025-03-31Redmile Group, LLC0.61190.7467647531700
2025-03-31Deep Track Capital, LP0.5680.2375601138000
2025-03-31ADAR1 Capital Management LLC0.56421.352359707684796455408.4477
2025-03-31Nantahala Capital Management, LLC0.47370.24350129273769414303.1262
2025-03-31Perceptive Advisors LLC0.41750.194418947-1461053-24.8478
2025-03-31BlackRock Inc0.22460.00012377187786593.4221
2025-03-31Column Group LLC0.12553.6651132861300
2025-03-31Geode Capital Management, LLC0.12350.0001130653558959882.2385
2024-12-31D. E. Shaw & Co LP0.07280.0009770013-278173-26.5385
2025-03-31State Street Corp0.06950735828365835.2318
2025-03-31Euclidean Capital LLC0.06220.301665789900
2025-03-31Acadian Asset Management LLC0.06140.00226493576353034520.4426
2025-03-31Renaissance Technologies Corp0.06130.001264882327908775.4828
Total 11.974124.5645126721408+36090262+28.5%

4.9.2. Funds holding RAPT Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv0.52090.0003551305800
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.13610.0013144040200
2025-05-31iShares Russell 2000 ETF0.06650.00170388400
2025-04-30Fidelity Extended Market Index0.04320.0012457382-4372-0.9468
2025-03-31Vanguard Strategic Small-Cap Equity Inv0.0380.0301401648-51672-11.3986
2025-03-31Fidelity Small Cap Index0.02910.0016308419-13251-4.1194
2025-03-31Vanguard Explorer Inv0.02820.0018298950-38459-11.3983
2025-05-31iShares Russell 2000 Value ETF0.02530.002226743900
2025-03-31Federated Hermes MDT SCG Institutional0.01780.0515188424-117861-38.4808
2025-03-31Federated Hermes MDT Small Cap Growth IS0.01780.0514188424-117861-38.4808
2025-03-31Vanguard Strategic Equity Inv0.01750.0027185514-23867-11.3988
2025-03-31Extended Equity Market Fund K0.01690.0017179161119567200.636
2025-03-31Vanguard VIF Small Co Gr0.01680.0161177563-22844-11.3988
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.01670.000417701300
2025-04-30Fidelity Total Market Index0.01530.000216209700
2025-04-30Vanguard Russell 2000 ETF0.0140.001214821882255.8753
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.01060.001211223200
2025-04-30Fidelity Series Total Market Index0.00980.0001103670-24399-19.0514
2025-03-31Bridgeway Ultra-Small Company Market0.00940.1246100000-25000-20
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.00920.0029769468328232.6772
Total 1.05910.292611211192-243466-2.2%

5.3. Insider Transactions

Insiders are holding 0.424% of the shares of RAPT Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-05Dirk G BrockstedtSELL112182.24
2023-12-21William HoSELL312173.44
2023-11-28William HoSELL187109.76
2023-10-03William HoSELL312126.16
2023-08-18William HoSELL312151.36
2023-04-19William HoSELL625151.04
2023-03-14Wendye RobbinsBUY312151.92
2023-03-07William HoSELL625236.96
2023-01-24William HoSELL625240
2023-01-19William HoSELL625204.48
2023-01-05Dirk G BrockstedtSELL92175.76
2022-12-29William HoSELL625144.24
2022-11-28William HoSELL625142.96
2022-11-02William HoSELL625178.56
2022-10-13William HoSELL250172.16
2022-08-30William HoSELL312225.04
2022-07-11William HoSELL250159.6
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets187,570
Total Liabilities10,198
Total Stockholder Equity177,372
 As reported
Total Liabilities 10,198
Total Stockholder Equity+ 177,372
Total Assets = 187,570

Assets

Total Assets187,570
Total Current Assets183,196
Long-term Assets4,374
Total Current Assets
Cash And Cash Equivalents 60,257
Short-term Investments 119,019
Other Current Assets 3,920
Total Current Assets  (as reported)183,196
Total Current Assets  (calculated)183,196
+/-0
Long-term Assets
Property Plant Equipment 3,985
Long-term Assets Other 389
Long-term Assets  (as reported)4,374
Long-term Assets  (calculated)4,374
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,678
Long-term Liabilities1,520
Total Stockholder Equity177,372
Total Current Liabilities
Short-term Debt 2,315
Accounts payable 1,295
Other Current Liabilities 5,068
Total Current Liabilities  (as reported)8,678
Total Current Liabilities  (calculated)8,678
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,520
Long-term Liabilities  (as reported)1,520
Long-term Liabilities  (calculated)1,520
+/-0
Total Stockholder Equity
Common Stock13
Retained Earnings -631,712
Accumulated Other Comprehensive Income 35
Other Stockholders Equity 809,036
Total Stockholder Equity (as reported)177,372
Total Stockholder Equity (calculated)177,372
+/-0
Other
Capital Stock13
Cash and Short Term Investments 179,276
Common Stock Shares Outstanding 53,853
Liabilities and Stockholders Equity 187,570
Net Debt -56,422
Net Invested Capital 177,372
Net Working Capital 174,518
Property Plant and Equipment Gross 14,296
Short Long Term Debt Total 3,835



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
69,610
67,860
68,109
58,369
84,602
150,889
139,676
128,970
118,969
105,924
231,081
217,462
198,636
187,548
221,996
209,489
266,209
248,326
220,756
199,721
173,329
155,818
127,180
108,465
240,325
187,570
187,570240,325108,465127,180155,818173,329199,721220,756248,326266,209209,489221,996187,548198,636217,462231,081105,924118,969128,970139,676150,88984,60258,36968,10967,86069,610000
   > Total Current Assets 
47,517
0
0
65,062
63,224
62,056
51,224
80,506
146,894
136,077
125,508
115,598
102,606
227,955
214,495
192,973
175,664
209,929
197,894
252,694
234,587
207,417
187,138
161,782
148,360
120,496
102,598
235,236
183,196
183,196235,236102,598120,496148,360161,782187,138207,417234,587252,694197,894209,929175,664192,973214,495227,955102,606115,598125,508136,077146,89480,50651,22462,05663,22465,0620047,517
       Cash And Cash Equivalents 
-47,517
0
0
63,798
61,758
59,862
48,310
77,383
91,529
28,957
20,229
24,918
24,720
86,220
59,999
24,027
32,418
57,203
27,706
38,946
45,768
50,164
54,135
47,478
45,317
37,077
37,900
169,735
60,257
60,257169,73537,90037,07745,31747,47854,13550,16445,76838,94627,70657,20332,41824,02759,99986,22024,72024,91820,22928,95791,52977,38348,31059,86261,75863,79800-47,517
       Short-term Investments 
95,034
0
0
0
0
0
0
0
46,670
103,993
102,557
86,592
73,686
137,084
150,787
165,627
140,590
150,138
167,730
210,122
185,861
154,834
130,642
111,384
96,262
77,761
60,005
61,320
119,019
119,01961,32060,00577,76196,262111,384130,642154,834185,861210,122167,730150,138140,590165,627150,787137,08473,68686,592102,557103,99346,670000000095,034
       Net Receivables 
0
0
0
0
0
0
0
0
5,010
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000005,01000000000
       Other Current Assets 
0
0
0
1,264
1,466
2,194
5,828
6,246
7,370
6,254
5,444
8,176
8,400
9,302
7,418
6,638
5,312
5,176
4,916
3,626
2,958
2,419
2,361
2,920
6,781
5,658
4,693
4,181
3,920
3,9204,1814,6935,6586,7812,9202,3612,4192,9583,6264,9165,1765,3126,6387,4189,3028,4008,1765,4446,2547,3706,2465,8282,1941,4661,264000
   > Long-term Assets 
-47,517
0
0
4,548
4,636
6,053
7,145
4,096
3,995
3,599
3,462
3,371
3,318
3,126
2,967
5,663
11,884
12,067
11,595
13,515
13,739
13,339
12,583
11,547
7,458
6,684
5,866
5,088
4,374
4,3745,0885,8666,6847,45811,54712,58313,33913,73913,51511,59512,06711,8845,6632,9673,1263,3183,3713,4623,5993,9954,0967,1456,0534,6364,54800-47,517
       Property Plant Equipment 
0
0
0
4,159
4,247
4,277
4,002
3,707
3,606
3,210
3,073
2,982
2,929
2,737
2,578
2,741
8,951
8,976
8,524
9,479
9,525
9,066
8,376
7,676
7,011
6,237
5,477
4,699
3,985
3,9854,6995,4776,2377,0117,6768,3769,0669,5259,4798,5248,9768,9512,7412,5782,7372,9292,9823,0733,2103,6063,7074,0024,2774,2474,159000
       Long-term Assets Other 
-47,517
0
0
389
389
1,776
3,143
389
389
389
-102,168
-86,203
389
389
389
2,922
2,933
3,091
3,071
4,036
4,214
4,273
4,207
3,871
447
447
389
389
389
3893893894474473,8714,2074,2734,2144,0363,0713,0912,9332,922389389389-86,203-102,1683893893893,1431,77638938900-47,517
> Total Liabilities 
0
0
0
5,612
173,611
8,103
183,166
11,481
18,960
17,065
18,923
14,790
14,283
13,502
15,589
12,256
19,713
19,863
20,183
21,043
27,856
21,079
26,921
26,294
24,983
17,960
12,959
50,421
10,198
10,19850,42112,95917,96024,98326,29426,92121,07927,85621,04320,18319,86319,71312,25615,58913,50214,28314,79018,92317,06518,96011,481183,1668,103173,6115,612000
   > Total Current Liabilities 
0
0
0
4,643
3,471
5,895
5,457
9,256
13,442
13,080
15,591
11,742
11,143
10,394
12,695
9,595
12,360
13,146
13,867
14,224
21,608
15,414
21,849
21,836
21,168
14,801
10,362
48,351
8,678
8,67848,35110,36214,80121,16821,83621,84915,41421,60814,22413,86713,14612,3609,59512,69510,39411,14311,74215,59113,08013,4429,2565,4575,8953,4714,643000
       Short-term Debt 
0
0
0
0
0
0
0
3,642
3,832
4,256
5,669
4,935
4,539
5,068
6,845
6,326
2,962
3,006
3,102
2,171
4,556
4,666
4,780
4,896
2,508
5,136
2,523
2,422
2,315
2,3152,4222,5235,1362,5084,8964,7804,6664,5562,1713,1023,0062,9626,3266,8455,0684,5394,9355,6694,2563,8323,6420000000
       Accounts payable 
0
0
0
1,771
1,320
2,604
1,590
1,143
3,409
2,381
4,405
2,383
3,131
2,714
4,017
1,999
1,936
4,097
4,043
3,365
8,941
2,690
5,297
5,176
6,771
2,716
1,380
1,275
1,295
1,2951,2751,3802,7166,7715,1765,2972,6908,9413,3654,0434,0971,9361,9994,0172,7143,1312,3834,4052,3813,4091,1431,5902,6041,3201,771000
       Other Current Liabilities 
0
0
0
2,872
2,151
3,291
3,867
4,113
4,268
4,686
6,058
5,263
4,877
5,397
7,140
6,580
6,817
6,043
6,722
8,688
8,111
8,058
11,772
11,764
11,889
6,949
6,459
44,654
5,068
5,06844,6546,4596,94911,88911,76411,7728,0588,1118,6886,7226,0436,8176,5807,1405,3974,8775,2636,0584,6864,2684,1133,8673,2912,1512,872000
   > Long-term Liabilities 
0
0
0
969
170,140
2,208
177,709
2,225
5,518
3,985
3,332
3,048
3,140
3,108
2,894
2,661
7,353
6,717
6,316
6,819
6,248
5,665
5,072
4,458
3,815
3,159
2,597
2,070
1,520
1,5202,0702,5973,1593,8154,4585,0725,6656,2486,8196,3166,7177,3532,6612,8943,1083,1403,0483,3323,9855,5182,225177,7092,208170,140969000
       Other Liabilities 
0
0
0
0
2,082
2,208
2,219
2,225
5,518
3,985
3,332
3,048
3,140
3,108
2,894
2,661
241
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002412,6612,8943,1083,1403,0483,3323,9855,5182,2252,2192,2082,0820000
       Deferred Long Term Liability 
0
0
0
0
0
0
2,800
0
0
0
0
3,048
3,140
3,108
2,894
2,661
241
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002412,6612,8943,1083,1403,04800002,800000000
> Total Stockholder Equity
46,238
0
0
63,998
-105,751
60,006
-124,797
73,121
131,929
122,611
110,047
104,179
91,641
217,579
201,873
186,380
167,835
202,133
189,306
245,166
220,470
199,677
172,800
147,035
130,835
109,220
95,506
189,904
177,372
177,372189,90495,506109,220130,835147,035172,800199,677220,470245,166189,306202,133167,835186,380201,873217,57991,641104,179110,047122,611131,92973,121-124,79760,006-105,75163,9980046,238
   Common Stock
0
0
0
2
1
2
1
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
13
13
1313333333333333332222221212000
   Retained Earnings -631,712-614,547-561,298-542,866-515,203-484,682-453,806-422,435-397,155-367,884-344,933-323,698-304,514-284,046-266,117-247,466-231,356-214,842-202,107-187,476-175,089-161,950-148,734-138,767-128,141-118,953000
   Capital Surplus 
0
0
0
0
22,884
23,265
23,923
235,049
307,009
0
0
319,196
323,184
465,179
467,942
470,629
473,463
526,573
534,689
613,073
617,283
622,289
0
0
0
0
0
0
0
0000000622,289617,283613,073534,689526,573473,463470,629467,942465,179323,184319,19600307,009235,04923,92323,26522,8840000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
0
0
0
21,245
22,884
23,265
-175,490
235,049
307,009
309,908
312,078
319,196
323,184
465,179
467,942
470,629
473,463
526,573
534,689
613,073
617,283
622,289
626,724
631,611
646,045
652,130
656,694
804,388
809,036
809,036804,388656,694652,130646,045631,611626,724622,289617,283613,073534,689526,573473,463470,629467,942465,179323,184319,196312,078309,908307,009235,049-175,49023,26522,88421,245000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-136,101
Operating Income-136,101-136,101
 
Operating Expense (+$)
Research Development107,217
Selling General Administrative28,884
Selling And Marketing Expenses0
Operating Expense136,101136,101
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-136,101
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-129,865-142,337
EBIT - interestExpense = -129,865
-129,865
-129,865
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-129,865-129,865
Earnings Before Interest and Taxes (EBITDA)-126,326
 
After tax Income (+$)
Income Before Tax-129,865
Tax Provision-0
Net Income From Continuing Ops-129,865-129,865
Net Income-129,865
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net6,2360
 

Technical Analysis of Rapt
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rapt. The general trend of Rapt is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rapt's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Rapt Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of RAPT Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.96 < 10.16 < 12.56.

The bearish price targets are: 6.88 > 5.664.

Know someone who trades $RAPT? Share this with them.👇

RAPT Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of RAPT Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

RAPT Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of RAPT Therapeutics Inc. The current macd is 0.06161595.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rapt price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Rapt. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Rapt price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
RAPT Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartRAPT Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of RAPT Therapeutics Inc. The current adx is 18.62.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Rapt shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
RAPT Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of RAPT Therapeutics Inc. The current sar is 7.32.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
RAPT Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of RAPT Therapeutics Inc. The current rsi is 49.53. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
RAPT Therapeutics Inc Daily Relative Strength Index (RSI) ChartRAPT Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of RAPT Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Rapt price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
RAPT Therapeutics Inc Daily Stochastic Oscillator ChartRAPT Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of RAPT Therapeutics Inc. The current cci is -37.25677276.

RAPT Therapeutics Inc Daily Commodity Channel Index (CCI) ChartRAPT Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of RAPT Therapeutics Inc. The current cmo is -3.15806032.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
RAPT Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartRAPT Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of RAPT Therapeutics Inc. The current willr is -60.47297297.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Rapt is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
RAPT Therapeutics Inc Daily Williams %R ChartRAPT Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of RAPT Therapeutics Inc.

RAPT Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of RAPT Therapeutics Inc. The current atr is 0.85199069.

RAPT Therapeutics Inc Daily Average True Range (ATR) ChartRAPT Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of RAPT Therapeutics Inc. The current obv is 13,337,137.

RAPT Therapeutics Inc Daily On-Balance Volume (OBV) ChartRAPT Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of RAPT Therapeutics Inc. The current mfi is 31.61.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
RAPT Therapeutics Inc Daily Money Flow Index (MFI) ChartRAPT Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for RAPT Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

RAPT Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern
2025-07-01Three Black Crows Candle Pattern

6.4. Technical Score

Let's check the technical score of RAPT Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.529
Ma 20Greater thanMa 508.409
Ma 50Greater thanMa 1007.680
Ma 100Greater thanMa 2008.329
OpenGreater thanClose8.060
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Rapt with someone you think should read this too:
  • Are you bullish or bearish on Rapt? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rapt? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about RAPT Therapeutics Inc

I send you an email if I find something interesting about RAPT Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about RAPT Therapeutics Inc.

Receive notifications about RAPT Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.